Date: Feb 23, 2015 Source: Company Data (
click here to go to the source)
OLATHE, Kan. -- Feb. 23, 2015 -- Metactive Medical Inc. (Metactive), an early-stage company focused on
developing embolization devices for the treatment of peripheral vascular and neurovascular diseases,
today announced that it has closed on $2 million of additional Series A financing, led by the Kansas
Bioscience Authority (KBA), an existing Metactive investor. Proceeds will be used to continue the
development of Metactive's novel embolic devices for occlusion of saccular aneurysms and peripheral
arteries and veins. Metactive previously raised $5 million in Series A funding, bringing the total funding
raised to date to $7 million.
"Metactive has shown immediate, complete and lasting occlusion of large saccular aneurysms with rapid
endothelialization of the aneurysm neck in a challenging nonclinical model, as well as similarly robust
performance with a peripheral occlusion device," said Tom Krol, Managing Director at KBA and a member
of Metactive's board of directors. "Clinicians treat thousands of saccular aneurysms and peripheral
arteries and veins each year. We believe that Metactive's devices have the potential to be better for
patients, faster and easier for physicians to use, and less expensive for payers."
Metactive also announced today the appointment of David Ferrera to its board of directors. Ferrera is
currently President and Chief Technology Officer of Blockade Medical and has 20 years of leadership
experience in the medical device industry at several market-leading neurovascular firms, including
MindFrame, Microvention and Micrus Endovascular.
"I am pleased to have the resources to accelerate the development of our novel, potentially life-saving
products and to welcome David to our board to help us realize our goal of providing physicians faster,
better and less expensive options for vascular occlusion," said F. Nicholas Franano, MD, President and
CEO of Metactive.
About Peripheral Artery and Aneurysm Embolization
Embolization is a minimally invasive treatment that blocks the flow of blood in selected segments of
arteries and veins, enabling physicians to divert blood away from cancerous tumors and other abnormal
tissues, as well as from damaged or malformed segments of blood vessels. More than 150,000 peripheral
vascular embolization procedures are performed each year worldwide using coils and vascular plugs.
Similarly, more than 150,000 cerebral aneurysm embolization procedures are performed worldwide each
year using coils and flow-diverting vascular stents. There is currently a need in these markets for
endovascular embolization devices that can be placed quickly and easily, with a high degree of precision,
and that result in immediate and lasting occlusion.
About Metactive Medical
Metactive is developing novel endovascular medical devices for the treatment of neurovascular and
peripheral vascular diseases. Metactive's first products enable precise and immediate occlusion and rapid
sealing of cerebral aneurysms and other target vessel segments using an over-the-wire microcatheter
platform. For more information, please visit www.metactivemedical.com.
Company Contact: Media Contact:
F. Nicholas Franano, MD, President and CEO Kari Watson
Metactive Medical Inc. MacDougall Biomedical Communications
(816) 550-9177 781-235-3060
nfranano@metactivemedical.com kwatson@macbiocom.com
